X 910279

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584721

CAS#: 185915-32-6

Description: X 910279 is a leflunomide analog and a malononitrilamide.

Chemical Structure

X 910279
CAS# 185915-32-6

Theoretical Analysis

MedKoo Cat#: 584721
Name: X 910279
CAS#: 185915-32-6
Chemical Formula: C14H11N3O2
Exact Mass: 253.09
Molecular Weight: 253.261
Elemental Analysis: C, 66.40; H, 4.38; N, 16.59; O, 12.63

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: X 910279; HMR 1279; HMR 279; MNA 279; MNA-279; X91 0279

IUPAC/Chemical Name: Cyclopropanepropanamide, alpha-cyano-N-(4-cyanophenyl)-beta-oxo-


InChi Code: InChI=1S/C14H11N3O2/c15-7-9-1-5-11(6-2-9)17-14(19)12(8-16)13(18)10-3-4-10/h1-2,5-6,10,12H,3-4H2,(H,17,19)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 253.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Schorlemmer HU, Bartlett RR, Schleyerbach R. Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis. Transplant Proc. 1998 Dec;30(8):4137-9. PubMed PMID: 9865326.

2: Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR. Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis. Inflamm Res. 1999 Dec;48 Suppl 2:S113-4. PubMed PMID: 10667840.

3: Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. Transplant Proc. 1999 Feb-Mar;31(1-2):1184-8. PubMed PMID: 10083529.

4: Slauson SD, Silva HT, Sherwood SW, Morris RE. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett. 1999 Apr 15;67(3):179-83. PubMed PMID: 10369124.

5: Schorlemmer HU, Kurrle R. Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. Transplant Proc. 1998 Dec;30(8):4170-3. PubMed PMID: 9865337.

6: Schorlemmer HU, Kurrle R, Schleyerbach R, Bartlett RR. Generation of O2- radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite. Inflamm Res. 1999 Dec;48 Suppl 2:S117-8. PubMed PMID: 10667842.

7: Schorlemmer HU, Bartlett RR, Lindner JK, Kurrle R. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Transplant Proc. 1998 Dec;30(8):4099-103. PubMed PMID: 9865312.

8: Schorlemmer HU, Bartlett RR. Modulation of immunoglobulin dysregulation in graft versus host-and systemic lupus erythematosus-like diseases by malononitrilamides. Transplant Proc. 1998 Dec;30(8):4153-5. PubMed PMID: 9865331.

9: Schorlemmer HU, Bartlett RR, Kurrle R. Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Transplant Proc. 1999 Feb-Mar;31(1-2):851-3. PubMed PMID: 10083371.

10: Czech J, Kurrle R, Schorlemmer HU. The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine. Inflamm Res. 1999 Dec;48 Suppl 2:S128-9. PubMed PMID: 10667848.

11: Slauson S, Billingham ME, Silva HT, Wang Y, Morris RE. Quilty effect in heterotopic cardiac allografts in malononitrilamide-treated rats. J Heart Lung Transplant. 1999 Dec;18(12):1251-3. PubMed PMID: 10612388.